The new company will be called "Tryptamine Therapeutics Limited," and will trade on the ASX under the ticker symbol "TYP"....
The agency contends that "Right-to-Try" laws do not supersede the Controlled Substances Act. The post DEA resists permitting psilocybin for terminal patients...
Clearmind said it will get exclusive rights to develop and commercialize psychedelic products from the University. The post Clearmind signs agreement with...
The company issued common shares to settle debts after the reporting period. The post Going concern warnings cloud Xtacy Therapeutics’ shrunk losses...
Numinus is selling or discontinuing its Canadian operations and will focus on the U.S. The post Numinus reports declining revenue as the company restructures...
Biopharmaceutical company Synaptogenix, Inc. (Nasdaq: SNPX) has increased its stake in the psilocybin drug discovery company PsygaBio through its previously...
The study is an attempt to revive ancient healing practices using natural medicines among the Māori people. The post Canada’s Optimi Health to ship...
Filament and Jaguar have been importing coca leaves into Canada. The post Filament’s pivots pay off, nets $2.1M revenue in 2023 appeared first on Green...
The upcoming study will compare the effects of DMT and a placebo in stroke patients. The post Algernon sells Ifenprodil, zooms in on DMT for stroke...
The firm said it feels comfortable about its runway through 2026. The post Atai cash purse down nearly half despite lower spending appeared first on Green...
